Arcutis Biotherapeutics Set to Showcase Key Research at AAD Annual Meeting

The first poster presentation will focus on pooled safety and local tolerability data for roflumilast cream 0.15%. This research stems from the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 trials and targets adults and children as young as six who have previously experienced inadequate responses, intolerance, or contraindications to topical treatments, including topical steroids.

Poster Details:

The second poster will detail findings from the ARRECTOR trial, showcasing the significant improvements in patient-reported outcomes related to roflumilast foam 0.3%. This presentation highlights the efficacy of the foam in treating scalp and body psoriasis in individuals over the age of 12.

Poster Details:

Patrick Burnett, MD, PhD, FAAD, Arcutis’ Chief Medical Officer, expressed enthusiasm about presenting this data, stating, “Highlighting additional data from our clinical development program for ZORYVE foam in scalp and body psoriasis and ZORYVE cream in atopic dermatitis reinforces the strong need for well-tolerated treatments among diverse patient populations, including those intolerant to steroids or who have had an inadequate response.” Burnett expressed confidence that these treatments may significantly improve the lives of individuals suffering from chronic inflammatory skin conditions.

In addition to the poster presentations, Arcutis will host two experiential learning sessions at its booth (Booth 1361) in collaboration with Dr. Candrice Heath of the Heath Health Foundation for Education and Research. These sessions will focus on Culturally Conscious Dermatology™, providing attendees with valuable insights into culturally sensitive dermatological care and scalp examination techniques.

Session Schedule:

ZORYVE is a next-generation topical phosphodiesterase-4 (PDE4) inhibitor, targeting chronic inflammatory skin conditions. The cream formulations, including roflumilast cream 0.3% and roflumilast cream 0.15%, have received FDA approval for the treatment of plaque psoriasis and mild to moderate atopic dermatitis, respectively. Additionally, ZORYVE foam is approved for seborrheic dermatitis in patients aged nine and older, with further indications for scalp and body psoriasis currently under FDA review.

Arcutis Biotherapeutics is dedicated to innovating in the field of medical dermatology, addressing the urgent needs of patients suffering from immune-mediated dermatological diseases. With a growing portfolio of FDA-approved products and a robust pipeline targeting various skin conditions, Arcutis is well-positioned to impact the landscape of dermatological care.

The AAD Annual Meeting presents an opportunity for Arcutis to share its latest findings and engage with the dermatology community, reinforcing its commitment to advancing patient care and treatment efficacy in the realm of dermatology.